Omnipaque (iohexol).
The largest nationwide comparative clinical study evaluated 337,647 patients receiving high-osmolar ionic contrast media or low-osmolar nonionic contrast media and the incidence of adverse drug reactions. The overall prevalence of adverse drug reactions was 12.66% in the ionic contrast media group and 3.13% in the nonionic contrast media group. Severe adverse drug reactions occurred in 0.22% of examinations in the ionic contrast media group and in 0.04% of examinations in the nonionic contrast media group. Thus, the use of nonionic contrast medium significantly reduces the frequency of severe and potentially life-threatening adverse drug reactions to contrast media.
Claussen
D
D
D002760:Cholangiopancreatography, Endoscopic Retrograde; D000075202:Contraindications; D004347:Drug Interactions; D006801:Humans; D007472:Iohexol / Q000009:adverse effects
D007472:Iohexol